News
-
-
-
COMMUNIQUÉ DE PRESSE
Results of the 2026 Annual General Meeting for the 2024/25 financial year of BRAIN Biotech AG
Results of the 2026 Annual General Meeting for the 2024/25 financial year of BRAIN Biotech AG. Shareholders approve all agenda items. New member elected to the Supervisory Board. CEO highlights company's strategy and unique selling points -
-
-
COMMUNIQUÉ DE PRESSE
BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure: Aurase Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds
BRAIN Biotech's Q1 25/26 results show revenue decline but improved EBITDA. Breakthrough Aurase Wound Gel by SolasCure for chronic wounds. BRAIN BioIncubator segment thrives -
-
-
COMMUNIQUÉ DE PRESSE
FY 2024/25: BRAIN Biotech AG benefits from successful monetization of projects and strong corporate cost control
BRAIN Biotech AG reports FY 2024/25 financial results showing successful project monetization and cost control measures. Decline in revenues offset by strong cash position -
